Journal
MELANOMA RESEARCH
Volume 24, Issue 2, Pages 177-180Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CMR.0000000000000047
Keywords
monoclonal antibodies; breast milk; melanoma; melanoma therapy
Categories
Ask authors/readers for more resources
Recently, therapeutic monoclonal antibodies have been introduced for the treatment of advanced melanoma and other diseases. It remains unclear whether these drugs can be safely administered to women who are breast feeding because of the potential hazardous side effects for nursing infants. One such therapy for metastatic melanoma is ipilimumab, a human monoclonal antibody that blocks cytotoxic T-lymphocyte-antigen-4, and is the preferred treatment for patients with metastatic melanoma when other molecular therapies are not viable. This study measured ipilimumab levels in the breast milk of a patient undergoing treatment that were enough to raise concerns for a nursing infant exposed to ipilimumab.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available